Rigel Pharmaceuticals Stock Price. Everything You Need To Know About The Rigel Pharmaceuticals Stock!
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California. With a team of 155 full-time employees, the firm is committed to discovering, developing, and providing therapies that improve the lives of patients with hematologic disorders and cancer.
The company, which went public on November 29th, 2000, has made significant progress in developing innovative therapies for chronic immune thrombocytopenia (ITP) and relapsed or refractory (R/R) acute myeloid leukemia (AML). Rigel’s lead product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, is a spleen tyrosine kinase (SYK) inhibitor that has shown promise in the treatment of adult patients with chronic ITP.
In addition to TAVALISSE, Rigel has other product candidates in clinical development, including REZLIDHIA (olutasidenib) capsules, which are for the treatment of adult patients with AML. The company’s clinical programs also include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program, both of which are in development.
For investors interested in the biotech industry, Rigel Pharmaceuticals offers a unique opportunity to support the development of innovative therapies that can improve patient outcomes. To make informed investment decisions, it’s important to stay up to date on the latest developments in the stock market, including premarket trends and stocks share price today. By regularly researching Rigel and its competitors, investors can stay informed about industry trends and changes in the stock price, enabling them to make informed decisions about buying, holding, or selling shares of this innovative biotech company.
Rigel Pharmaceuticals Stock Price. Everything You Need To Know About The Rigel Pharmaceuticals Stock! performance
- Employees 155
- Company HQ South San Francisco
- Website https://www.rigel.com/
- RIGL Asset Type Common Stock
- RIGL Market Capitalization 192.9M
- Earnings Per Share -0.14
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth -0.479
Rigel Pharmaceuticals is a dynamic and innovative company in the biotechnology sector, with a strong focus on developing breakthrough therapies for immune and hematologic disorders. As an investor from Malaysia, Thailand, Indonesia, or Vietnam, you have the opportunity to invest in this promising stock and gain exposure to the rapidly growing biotech industry. To invest in Rigel Pharmaceuticals, start by opening an account with Zorion, the leading investment platform for retail investors from these countries. With access to real US stocks and Pre-IPO companies, Zorion provides a seamless and user-friendly experience to help you make informed investment decisions. To maximize your investment knowledge, Zorion also offers a wide range of resources and educational materials. Brush up your understanding of the biotech industry, learn about Rigel’s pipeline of potential treatments, and stay updated with the latest market trends through Zorion’s expert insights and recommendations. Investing in Rigel Pharmaceuticals from Malaysia, Thailand, Indonesia, or Vietnam has never been easier. Take advantage of Zorion’s comprehensive investment tools and start making informed investment decisions today.
